The Role of Temozolomide-Irinotecan in Doxorubicin- Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?
Mathews Journal of Cancer Science · 2020
DOI: 10.30654/mjcs.10026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mathews Journal of Cancer Science, 2020. Verfasst von Maher Salamoon und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Salamoon, M., Balti, M., Farnault, B., Saifo, M., Mahmoud, A., Khatib, A., Daghlawi, M., Husein, T., Kenj, M., & Ghanem, K. (2020). The Role of Temozolomide-Irinotecan in Doxorubicin- Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?. Mathews Journal of Cancer Science. https://doi.org/10.30654/mjcs.10026
Vancouver
Salamoon M, Balti M, Farnault B, Saifo M, Mahmoud A, Khatib A, et al. The Role of Temozolomide-Irinotecan in Doxorubicin- Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?. Mathews Journal of Cancer Science. 2020. doi:10.30654/mjcs.10026
BibTeX
@article{Salamoon2020,
author = {Salamoon, Maher and Balti, Mehdi and Farnault, Bertrand and Saifo, Maher and Mahmoud, Ali and Khatib, Ahmad and Daghlawi, Manal and Husein, Taisir and Kenj, Mazen and Ghanem, Khaled},
title = {The Role of Temozolomide-Irinotecan in Doxorubicin- Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?},
journal = {Mathews Journal of Cancer Science},
year = {2020},
doi = {10.30654/mjcs.10026}
}
EUVIMED